62 results about "Dihydrochalcone" patented technology

The invention is applicable to the technical field of biological medicines, provides application of a natural compound of a targeted colon cancer drug resistance related protein, and particularly relates to application in preparation of drugs for preventing or treating colon cancer. According to the invention, a natural small molecule compound neohesperidin dihydrochalcone targeting the colon cancer drug resistance related protein TAGLN is screened out, and a new scheme is provided for reversing colon cancer drug resistance, so that the situation that no drug is available to the target spot is solved. Secondly, the invention also provides a scheme for combined use of neohesperidin dihydrochalcone and oxaliplatin, the scheme can significantly enhance the killing effect of oxaliplatin on drug-resistant colon cancer, and a new choice is provided for clinical treatment of colon cancer.

The invention discloses a NHDC / pyruvic acid binary liquid supramolecular self-assembly system and a preparation method thereof, and belongs to the field of supramolecular technology. The method for preparing the neomethyl hesperidin dihydrochalcone / pyruvic acid binary liquid supramolecular self-assembly system of the invention comprises: mixing pyruvic acid and neomethyl hesperidin dihydrochalcone to prepare the neomethyl hesperidin dihydrochalcone / pyruvic acid binary liquid supramolecular self-assembly system. The method of the invention significantly improves the water solubility, antioxidant property and antibacterial property of the neomethyl hesperidin dihydrochalcone.

The present disclosure generally relates to dihydrochalcone compounds and their use for enhancing the perception of alcohol (ethanol) in food, beverages, and other comestible compositions. In certain aspects, the disclosure provides the use of such dihydrochalcone compounds to enhance an alcoholic (ethanolic) flavor of a beverage, for example, a low-alcohol or zero-alcohol beverage. In certain other aspects, the disclosure provides low-alcohol or zero-alcohol beverages containing such dihydrochalcone compounds.

The application belongs to the technical field of biological medicine, and provides application of a natural compound targeting colon cancer drug resistance related protein, in particular, application in preparation of a drug for preventing or treating colon cancer; the application screens out a natural small-molecule compound hesperetin dihydrochalcone targeting colon cancer drug resistance related protein TAGLN, and provides a new scheme for reversing colon cancer drug resistance, so as to solve the situation that no drug is available for the target point. In addition, the application further provides a scheme in which hesperetin dihydrochalcone is combined with oxaliplatin, and the scheme can significantly enhance the killing effect of oxaliplatin on drug-resistant colon cancer, thereby providing a new choice for clinical treatment of colon cancer.

The invention discloses an NHDC / cyclodextrin / pyruvic acid ternary liquid supramolecular self-assembly system and a preparation method thereof, and belongs to the technical field of supramolecules. The invention provides a new methyl hesperidin dihydrochalcone / cyclodextrin / pyruvic acid ternary liquid supramolecular self-assembly system and a preparation method thereof by selecting molecules compatible with new methyl hesperidin dihydrochalcone, the types of the compatible molecules and the addition amount. The neohesperidin dihydrochalcone / cyclodextrin / pyruvic acid system obtained through supramolecular self-assembly is in a stable liquid state and can be mixed and dissolved with water in a specific proportion without precipitation, and the water solubility, stability, oxidation resistance and antibacterial property of neohesperidin dihydrochalcone are effectively improved.

To provide a sweetener-containing food and beverage product with improved sweetness quality.SOLUTION: The sweetener-containing food and beverage product contains dihydrochalcones and minerals, and the amounts of dihydrochalcones and minerals are adjusted to a specified range.SELECTED DRAWING: None

The present invention relates to a confectionery containing psicose. Specifically disclosed is a sugar-free confectionery composition which is a jelly confectionery wherein the confectionery comprises: from 1% to 50% by weight of psicose; and from 1% to 50% of a polyol incremental sweetener in combination with a high-potency sweetener wherein the polyol incremental sweetener is selected from the group consisting of sorbitol, maltitol, isomaltitol, mannitol, xylitol, erythritol, and lactitol, and the high-potency sweetener is selected from the group consisting of kiwifruit protein, aspartame, acesulfame K, saccharin sodium, glycyrrhizin, Alisan, cyclohexylsulfamate, stevioside, dihydrochalcone, stevioside, stevioside, glycosylated stevioside, and Momordica grosvenori, and wherein the confectionery composition has a moisture content of from 15% to 20%, and wherein the sweetener is selected from the group consisting of ketoside, aspartame, acesulfame K, saccharin sodium, glycyrrhizin, Alisan, cyclohexylsulfamate, stevioside, dihydrochalcone, stevioside, glycosylated stevioside, and Momordica grosvenori; a method of making the sugar-free confectionery composition is also disclosed. The present invention provides a low calorie, low laxative confection comprising psicose with acceptable texture, stability, clarity, flavor delivery, and shelf life.

This invention discloses the application of plant extracts in the preparation of drugs that inhibit canine parvovirus, belonging to the field of biomedical technology. The plant extract is at least one selected from phlorizin, neomethylhesperidin-dihydrochalcone, tribulus terrestris saponin, stevia glycoside, soy isoflavones, berberine hydrochloride, diosgenin, and silymarin. Through in-depth research on various plant extracts, this invention has found that phlorizin, neomethylhesperidin-dihydrochalcone, tribulus terrestris saponin, stevia glycoside, soy isoflavones, berberine hydrochloride, diosgenin, and silymarin all exhibit significant inhibitory effects on canine parvovirus, with soy isoflavones showing particularly outstanding effects. This research provides a novel natural drug option for the prevention and treatment of canine parvovirus. This invention not only expands the application scope of natural plant extracts in the veterinary medicine field but also provides important technical support for the development of novel, highly effective, safe, and side-effect-free drug formulations for the prevention and treatment of canine parvovirus.

The present disclosure generally relates to 3-alkoxyflavanone compounds and the use of such compounds to impart and / or enhance sweetness, mask bitterness, improve texture, or mask astringency. In certain embodiments, such compounds are used in combination with other flavonoids or dihydrochalcones. In certain aspects, the present disclosure provides ingestible compositions comprising such flavanone compounds. In some related aspects, the ingestible compositions are or are included in various flavored products, such as food, beverage products, pharmaceuticals, or oral care products.

A flavor composition is provided. The composition includes a dihydrochalcone selected from the group consisting of hesperetin dihydrochalcone, hesperetin dihydrochalcone 4"-beta-D-glucoside, and combinations thereof, and an aromatic ingredient selected from the group consisting of 4-hydroxy-2H-furan-5-one, ethyl furanone, maltol, furfural, 5-methylfurfural, vanillin, benzaldehyde, and combinations thereof.

The present disclosure generally relates to certain flavanone compounds and the use of such compounds to modify the flavor or taste of an ingestible composition. These flavanone compounds include 8-methylnaringenin (5,7,4'-trihydroxy-8-methylflavanone), 5,3'-dihydroxy-7,4'-dimethoxyflavanone, 5-hydroxy-7,3',4'-trimethoxyflavanone, 5,4'-dihydroxy-7,3'-dimethoxyflavanone, or any combinations thereof. In some embodiments, the use of these flavanone compounds includes their use to enhance a sweet taste, their use to reduce an off taste of a high-intensity sweetener, their use to enhance a salty taste, their use to enhance an umami or kokumi taste, or any combination thereof. In certain embodiments, such compounds are used in combination with other natural taste modifiers, such as flavonoids or dihydrochalcones. In certain aspects, the disclosure provides ingestible compositions that include such flavanone compounds. In some related aspects, the ingestible compositions are, or are included within, various flavored products, such as food products, beverage products, pharmaceutical products, oral care products, or animal feed products.

To provide a packaged beverage containing water-insoluble particles that have a 90% cumulative particle diameter (D90) of 1-500 μm, the packaged beverage reduced in unpleasant sandy mouthfeel remaining on the tongue after drinking.SOLUTION: The production of a packaged beverage containing water-insoluble particles includes: a step of preparing a beverage by including a plant raw material containing water-insoluble particles and dihydrochalcones such that the 90% cumulative particle diameter (D90) of the water-insoluble particles is 1-500 μm; and a step of heat-sterilizing the beverage.SELECTED DRAWING: None

The purpose of the present invention is to improve the quality of sweetness in a food or beverage containing a sweetener. According to the present invention, in a food or beverage containing a sweetener, the food or beverage contains dihydrochalcones and minerals, and the content of dihydrochalcones and minerals is adjusted to a prescribed range.

The present disclosure generally relates to certain fatty acid amide compounds, such as hydroxy-α-sanshools, hydroxy-β-sanshools, and hydroxy-γ-sanshools, and the use of such compounds to impart or enhance sweetness, as well as mask bitterness, enhance mouthfeel, or mask astringency. In certain embodiments, such compounds are used in combination with other sweeteners or sweetness enhancers, such as flavonoids or dihydrochalcones. In certain aspects, the disclosure provides ingestible compositions that include such fatty acid amides. In some related aspects, the ingestible compositions are, or are included within, various flavored products, such as food products, beverage products, pharmaceutical products, or oral care products.

The purpose of the present invention is to improve the quality of sweetness in a food or beverage containing a sweetener.　A dihydrochalcone and a mineral are added to a food or beverage containing a sweetener, and the content of each of the dihydrochalcone and the mineral is adjusted to a value falling within a specified range.

The present disclosure provides a use of a compound of Formula (I), wherein: - one of A and B is H and the other is (II); - G is R2 and E is H, -CH2-E' or (III), or G and E' are both single carbon atoms, said carbon atoms being directly linked together by a single bond, G being substituted by (IV) and E' being substituted by R6; - Re is H or OR1; - Rf is H or OR8, wherein R8 is H or C1-C12 alkyl; - each of R1, R2, R3, and R4 is independently H or C1-C12 alkyl; and - each of R5, R6, and R10 is independently H, OH, C1-C12 alkyl, or C1-C12 alkoxy, or a salt, ester, or solvate thereof, for preventing or reducing Legionella growth. Also provided is a kit comprising the compound.

The present invention provides a chalcone reductase mutant and its application. The mutant is obtained by the following single mutations at position 120 or 121 of the amino acid sequence of wild-type chalcone reductase: H120G / R / I / N, W121R / C / N / P / L / Q / A / F / Y. The present invention screens for chalcone reductase mutants with significantly higher selective catalytic reduction activity than the wild type by the activity of selectively catalytically reducing the carbon-carbon double bond of chalcone for the above mutants. The method of using the chalcone reductase described in the present invention as a biocatalyst for selectively reducing the carbon-carbon double bond of chalcone to synthesize dihydrochalcone has the advantages of simple reaction steps, mild reaction conditions, high catalytic efficiency, easy enzyme preparation, good thermal stability, etc., and mutants with catalytic performance significantly superior to the wild type are discovered. The present invention is of great significance for the industrial application of chalcone reductase and improves the application ability of chalcone reductase in selectively reducing the carbon-carbon double bond of chalcone.

A flavor composition is provided. The composition includes a dihydrochalcone selected from the group consisting of hesperetin dihydrochalcone, hesperetin dihydrochalcone 4″-beta-D-glucoside, and combinations thereof, and an aroma ingredient selected from the group consisting of furonol, ethyl furanone, maltol, furfural, 5-methyl furfural, vanillin, benzaldehyde, and combinations thereof.

The application relates to the application of natural plant extracts in the field of oral health, and particularly discloses the application of an extract of Ilex hainanensis Merr in oral health care products. The Ilex hainanensis Merr dichloromethane extract is eluted by high-concentration ethanol through a macroporous resin, and is rich in dihydrochalcone active ingredients, has significant inhibitory activity on Porphyromonas gingivalis and Fusobacterium nucleatum, and has no inhibitory effect on Streptococcus mutans, can selectively inhibit periodontal pathogenic bacteria without destroying the oral microecological balance, and is suitable for preparing toothpaste, mouthwash, oral spray and other oral health care products.

A flavor composition is provided. The composition includes at least one triterpenoid compound selected from the group consisting of pterocaryoside B, pterocaryoside A, cyclocarioside K and combinations thereof; and at least one sweetness modifier selected from the group consisting of steviol glycosides, mogrosides, dihydrochalcones, sweet proteins and combinations thereof.

The invention discloses a leucaena leucocephala-sourced dihydrochalcone compound, a preparation method thereof and application of the dihydrochalcone compound as a tyrosinase inhibitor. According to the invention, the tyrosinase inhibitor dihydrochalcone compound (+ / -)-4, 4 '-Methoxy-3, 3', beta-trihydroxydihydroxychalcone is extracted and separated from the leucaena leucocephala plant, the structural formula of the compound is as shown in the formula (I), the plant material is rich in source and is a renewable tissue part, and not only is the economic benefit good, but also the environment-friendly effect is achieved. Pharmacological experiments show that the tyrosinase inhibitory activity of the compound (+ / -)-4, 4 '-Methoxy-3, 3', beta-trihydroxydihydroxycholone is stronger than that of kojic acid, and the compound (+ / -)-4, 4 '-Methoxy-3, 3', beta-trihydroxydihydroxycholone) is expected to be further developed into a new whitening cosmetic synergist, a drug for treating pigmentation dermatosis, an insect control agent or a food preservative and the like, and has a good prospect.

Provided herein is a method of increasing production of a dihydrodiphenylpropanoid derivative compound (e.g., dihydrostilbenoid or dihydrochalcone compound) in a recombinant host cell. The method comprising: reducing or eliminating expression of a gene encoding a double-bond reductase polypeptide or activity of the double-bond reductase polypeptide encoded thereby; expressing a recombinant gene encoding a double-bond reductase selected from the group consisting of a first polypeptide, second polypeptide, third polypeptide, and combinations thereof. The first polypeptide comprises an amino acid sequence having at least 90% identity to the amino acid sequence as set forth in SEQ ID NO: 3, the second polypeptide comprises an amino acid sequence having at least 90% identity to the amino acid sequence as set forth in SEQ ID NO: 5, and the third polypeptide comprises an amino acid sequence having at least 90% identity to the amino acid sequence as set forth in SEQ ID NO: 7.

A flavor composition is provided. The composition includes a dihydrochalcone selected from the group consisting of hesperetin dihydrochalcone, hesperetin dihydrochalcone 4″-beta-D-glucoside, and combinations thereof, and an aroma ingredient selected from the group consisting of furonol, ethyl furanone, maltol, furfural, 5-methyl furfural, vanillin, benzaldehyde, and combinations thereof.

The invention discloses application of a plant extract in preparation of a medicine for inhibiting canine parvovirus, and relates to the technical field of biological medicine. The plant extract is at least one of phloretin, neohesperidin-dihydrochalcone, tribulus terrestris saponin, rubusoside, soy isoflavone, berberine hydrochloride, dioscin and silymarin. In-depth study on various plant extracts shows that phloretin, neohesperidin-dihydrochalcone, tribulus terrestris saponin, rubusoside, soy isoflavone, berberine hydrochloride, dioscin and silymarin all show a remarkable canine parvovirus inhibition effect, and the effect of soy isoflavone is particularly outstanding. The research result provides a brand new natural medicine choice for preventing and treating canine parvovirus. The application range of natural plant extracts in the field of veterinary medicine is expanded, and important technical support is provided for developing novel, efficient and safe canine parvovirus prevention and treatment medicine preparations without side effects.

A perfume composition is provided. The present invention relates to a composition comprising rutin and a sweetness modifier selected from the group consisting of mogroside, dihydrochalcone, hesperidin 3-acetate, brazilin, thaumatin, and combinations thereof.

A perfume composition is provided. The composition comprises amyrin 3-acetate, and a compound as shown in the specification, and at least one sweetness modifier selected from the group consisting of stevioside, mogroside, dihydrochalcone, sweet protein, and combinations thereof.

The invention discloses a dihydrochalcone glucoside compound with the following structural formula, which is separated from malus toringoides, a high-fat model is obtained by inducing HepG2 cells through oleic acid, and the dihydrochalcone glucoside compound is used for treating the high-fat model, so that the dihydrochalcone glucoside compound is obtained. Experimental results show that the dihydrochalcone glycoside compound can effectively down-regulate accumulation of TG in human hepatoma cells (HepG2) treated by oleic acid at low concentration and reduce the number of lipid droplets, the effect is better than that of a positive drug fenofibrate, and the results show that the dihydrochalcone glycoside compound has a lipid-lowering effect and can be used for treating liver cancer cells (HepG2). The invention provides a new way for developing high-efficiency and low-toxicity lipid-lowering products; # imgabs0 #

The purpose of the present invention is to provide a packaged beverage containing water-insoluble particles that have a 90% cumulative particle diameter (D90) of 1-500 μm, wherein the packaged beverage allows for reduction in unpleasant mouthfeel that remains on the tongue after drinking.　The production of a packaged beverage containing water-insoluble particles includes: a step for preparing a beverage by including a plant raw material containing water-insoluble particles and dihydrochalcones so that the 90% cumulative particle diameter (D90) of the water-insoluble particles is 1-500 μm; and a step for heat-sterilizing the beverage.

The invention belongs to the technical field of traditional Chinese medicine detection, and particularly relates to a method for detecting the content of effective components of pseudo-ginseng and dragon's blood capsules. The invention provides a method for detecting the content of effective components in a pseudo-ginseng and dragon's blood capsule, which comprises the following steps: a, preparing a test solution: weighing pseudo-ginseng and dragon's blood capsule powder, adding methanol, performing ultrasonic treatment, and filtering to obtain the test solution; b, preparation of a reference substance solution: precisely weighing a ginsenoside Re reference substance, and adding methanol to dissolve the ginsenoside Re reference substance; the preparation method comprises the following steps: precisely weighing a proper amount of reference substances such as resveratrol, 4, 4-dihydroxy-2, 6-dimethoxy dihydrochalcone, loureirin A, loureirin B, loureirin C and loureirin D, and adding methanol for dissolving, thereby obtaining the resveratrol, 4, 4-dihydroxy-2, 6-dimethoxy dihydrochalcone and loureirin A; c, preparation of a reference substance solution: weighing the panax notoginseng total saponin reference extract, and adding methanol to dissolve the panax notoginseng total saponin reference extract to obtain the reference substance solution; and d, measuring and calculating the content. The method disclosed by the invention is high in accuracy, good in linearity, high in precision, good in separation degree and relatively good in repeatability.

The present disclosure provides pharmaceutical compositions comprising a microorganism capable of expressing an enzyme that converts a stilbene glycoside (e.g., polydatin) or a dihydrochalcone glycoside (e.g., phloridzin) to a stilbene (e.g., resveratrol) or a dihydrochalcone (e.g., phloretin), and a stilbene glycoside or a dihydrochalcone glycoside, or a pharmaceutically acceptable salt thereof. The present disclosure also provides methods for treating a Clostridioid.es difficile infection in a subject in need thereof comprising administering to the subject a therapeutically effective amount of any of the pharmaceutical compositions described herein. Methods for treating a Clostridioides difficile infection in a subject in need thereof comprising administering a therapeutically effective amount of a pharmaceutical composition comprising a stilbene glycoside, a dihydrochalcone glycoside, a stilbene, or a dihydrochalcone, or a pharmaceutically acceptable salt thereof, are also provided herein. The present disclosure further provides kits, food products, and nutraceuticals.